The low rate of clinical failures is a key limitation in interpreting the PK/PD targets used 138 for PTA analyses; however, the overall high clinical/microbiological success rates are 139 broadly consistent with the PK/PD analyses using joint target attainment criteria in 140 supporting the assigned ceftazidime-avibactam susceptible breakpoint (≤8 mg/L) 141 8 against both Enterobacteriaceae and P. aeruginosa. Moreover, surveillance data 142 confirm that the MIC cutoff of ≤8 mg/L separates ceftazidime-avibactam resistant MBL-143 carrying isolates from those without known ceftazidime-avibactam resistance 144 mechanisms (3, 47, 48). These breakpoints define ≥90% of Enterobacteriaceae and P. 145 aeruginosa from contemporary global surveillance, including key antibiotic resistant sub-146 populations, as susceptible to ceftazidime-avibactam (3-6, 28-34).
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against genotypically-and phenotypically-characterized antibiotic-resistant sub-98 populations among the Enterobacteriaceae countered that idea. Figure 1A includes 99 meropenem-nonsusceptible isolates (3), and multi-drug-resistant (MDR: resistant to ≥3 100 classes of antibacterial agent) isolates (6), including 816 MBL-negative meropenem-101 nonsusceptible isolates. The 90 th percentile ceftazidime-avibactam MIC for these 102
isolates was 4 mg/L, with 97.7% inhibited by ≤8 mg/L (3), and the MIC distribution was 103 right-shifted compared to the whole distribution, with an upper cut-off of 4-8 mg/L i.e., 104 the susceptible breakpoint was at the upper end of, and did not divide, the MIC 105 distribution against this critical phenotypically-and genotypically-defined sub-population. 106
The 34,062 Enterobacteriaceae isolates ( Figure 1A ) also included 2,739 MDR Klebsiella 107 pneumoniae and 82 MDR Klebsiella oxytoca. The ceftazidime-avibactam MIC was ≤2 108 mg/L against 90% of these isolates, and ≤8 mg/L against 96.6% (6); again, the MIC 109 distribution was right-shifted compared with the overall distribution, and the susceptible 110 breakpoint was at the upper end of, but did not divide, that distribution. From these 111 analyses, it is clear that a breakpoint of ≤8 mg/L is necessary to encompass important 112 antibiotic resistant sub-populations such as carbapenem-resistant or MDR strains. 113
Phenotypical/genotypical sub-population analyses of P. aeruginosa were less helpful 114 than analyses of Enterobacteriaceae sub-populations, possibly because in 115 approximately 30% of ceftazidime-non-susceptible P. aeruginosa the ceftazidime-116 resistance was not β-lactamase-mediated, not being reversed by combination with 117 avibactam (5). Eastern Europe, where MBL-producing P. aeruginosa are comparatively common (37, 123 38 
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Data pooled from the ceftazidime-avibactam arms of the microbiologically evaluable (ME) population of the Phase II 400 trial in patients with cIAI (NCT00752219) (39) and the extended ME (eME 
